Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 46; no. 8; pp. 1451 - 1459
• Main Authors: Dunn, Kelly E., Bergeria, Cecilia L., Huhn, Andrew S., Speed, Traci J., Mun, Chung Jung, Vandrey, Ryan, Campbell, Claudia M.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2021; Nature Publishing Group
• Subjects: 692/308/1426; 692/308/409; Adult; Adverse events; Analgesia; Analgesics, Opioid; Behavioral Sciences; Biological Psychology; Blindness; Cannabinoids; Capsaicin; Chronic pain; Clinical trials; Cognitive ability; Double-Blind Method; Dronabinol; Drug abuse; Humans; Hydromorphone; Laboratories; Medicine; Medicine & Public Health; Narcotics; Neurosciences; Opioids; Pain; Pain - drug therapy; Pain perception; Pharmacotherapy; Placebos; Psychiatry; Tetrahydrocannabinol

This Phase II study evaluated analgesia, abuse liability, and cognitive performance of hydromorphone and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within-subject, double-blind, randomized, placebo-controlled, human laboratory trial. Healthy adults ( N  = 29) with no history of drug...